<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01500681</url>
  </required_header>
  <id_info>
    <org_study_id>10-007339</org_study_id>
    <secondary_id>MultiPLEX-2012</secondary_id>
    <nct_id>NCT01500681</nct_id>
  </id_info>
  <brief_title>Maintenance Plasma Exchange for Neuromyelitis Optica</brief_title>
  <acronym>MultiPLEX</acronym>
  <official_title>A Prospective Observational Study of Maintenance Plasma Exchange (PLEX) for Neuromyelitis Optica Spectrum Disorders (MultiPLEX Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Terumo BCT</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neuromyelitis optica (NMO) is an inflammatory disease of the central nervous system that is
      associated with autoantibodies to aquaporin-4. Treatment options for prevention of clinical
      relapses of NMO include immunosuppressive medications. Plasma exchange (PLEX) is commonly
      used as a rescue therapy for NMO relapses but ongoing, regular PLEX procedures (maintenance
      PLEX) is sometimes used to prevent relapses. This observational registry will record
      feasibility, tolerability, safety, and preliminary efficacy data regarding maintenance PLEX
      for NMO.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Neuromyelitis optica (NMO) is an inflammatory disease of the central nervous system that is
      associated with autoantibodies to aquaporin-4. Treatment options for prevention of clinical
      relapses of NMO include immunosuppressive medications. Plasma exchange (PLEX) is commonly
      used as a rescue therapy for NMO relapses but ongoing, regular PLEX procedures (maintenance
      PLEX) is sometimes used to prevent relapses. This observational registry will record
      feasibility, tolerability, safety, and preliminary efficacy data regarding maintenance PLEX
      for participants with NMO, NMO spectrum disorders, and recurrent idiopathic longitudinally
      extensive transverse myelitis.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2012</start_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants who complete planned maintenance PLEX regimen</measure>
    <time_frame>One year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>One year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Annualized clinical relapse rate</measure>
    <time_frame>One year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median Expanded Disability Status Score (EDSS)</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Neuromyelitis Optica</condition>
  <condition>Neuromyelitis Optica Spectrum Disorder</condition>
  <condition>Recurrent Idiopathic Longitudinally Extensive Transverse Myelitis</condition>
  <arm_group>
    <arm_group_label>Maintenance PLEX</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Plasma exchange (PLEX)</intervention_name>
    <description>Regular maintenance PLEX courses, typically 3 procedures monthly</description>
    <arm_group_label>Maintenance PLEX</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Neuromyelitis optica/CNS demyelinating disease specialty clinics
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Neuromyelitis optica

          -  Neuromyelitis optica spectrum disorder

          -  Recurrent idiopathic longitudinally extensive myelitis

          -  Age 18 years or greater

        Exclusion Criteria:

          -  Any condition that in the opinion of the investigator could increase a participant's
             risk by participating in the observational study or confound the outcome of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dean M Wingerchuk, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 23, 2011</study_first_submitted>
  <study_first_submitted_qc>December 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2011</study_first_posted>
  <last_update_submitted>March 21, 2017</last_update_submitted>
  <last_update_submitted_qc>March 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Dean Wingerchuk</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuromyelitis Optica</mesh_term>
    <mesh_term>Myelitis</mesh_term>
    <mesh_term>Myelitis, Transverse</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

